Company Overview

Vaidya Sane Ayurved Laboratories Limited is an India-based company engaged in research and development in ayurvedic medicines and the sale of ayurvedic medicines and products through its various franchises and own clinics. The Company is involved in providing ayurvedic professional services across its various clinics, including panchkarma and other ayurvedic treatments through the running of ayurvedic hospitals. The company specializes in treating chronic medical conditions with a unique combination of modern and traditional methods. Founded in 1999, the company was converted to a Public Limited Company in 2021 with Dr. Rohit Madhav Sane as its present promoter.

The company was originally incorporated as a Private Limited Company pursuant to a Certificate of Incorporation issued by the Registrar of Companies Pune dated April 6, 1999, with the name 'Vaidya Sane Ayurved Laboratories Private Limited'. The transformation from a private entity to a public limited company reflects the organization's growth trajectory and expansion plans in the ayurvedic healthcare sector.

The company uses diagnostics, diet, physiotherapy, and ayurveda to provide heart disease, diabetes, hypertension, and obesity reversal treatments to its patients. This integrated approach combines traditional ayurvedic principles with modern diagnostic techniques, positioning the company as a comprehensive healthcare solution provider in the alternative medicine space.

Business Operations and Network

The Company operates approximately 337 clinics across Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Goa, Karnataka, Delhi, Haryana, Punjab, Himachal Pradesh, Uttarakhand, West Bengal, Jammu, Kerala, Orissa, and Chhattisgarh. It owns about 55 clinics, 59 are OPDs and Mini Clinics, and 223 are franchise clinics. This extensive network demonstrates the company's pan-India presence and its franchise-based expansion model, which helps in scaling operations while maintaining capital efficiency.

The company offers ayurvedic medication and products through its 274 clinics and 2 hospitals in Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Goa, and Karnataka, with 52 company-owned and 222 franchise clinics. The company also provides services such as panchkarma and other treatments in its clinics and hospitals. It operates a clinic-based healthcare delivery model along with telemedicine for easy accessibility to patients.

The company has embraced digital innovation to enhance patient accessibility. It has entered into MOUs and launched various programs, achieving 90,000 new patient registrations and 100,000 downloads of their MIB Pulse mobile application. These digital initiatives reflect the company's commitment to modernizing healthcare delivery while maintaining its core ayurvedic focus.

Financial Performance

Recent Financial Results (FY25)

For FY25, the company reported ₹89.85 Cr revenue and ₹7.15 Cr PAT, with cost cuts, new clinics, and hospital expansions planned. These figures from a May 27, 2025, earnings call demonstrate the company's financial stability and growth initiatives. The company published audited standalone and consolidated financial results for the FY ended March 31, 2025, on May 24, 2025.

Key Financial Metrics

- Market Capitalization: ₹172 Crore (as of recent reports, up 4.81% in 1 year)

- Revenue: ₹89.8 Cr for FY25

- Profit After Tax (PAT): ₹7.14 Cr for FY25

- Book Value Multiple: Stock is trading at 2.78 times its book value

- Promoter Holding: 66.3%

Historical Financial Data

For the year ended 2024, Vaidya Sane Ayurved Laboratories Ltd had posted a profit of ₹1.99 crore on a total income of ₹99.33 crore. Comparing this with FY25 results shows significant improvement in profitability, with PAT growing from ₹1.99 Cr to ₹7.15 Cr, representing substantial growth in bottom-line performance.

The company has an operating revenue of ₹198.66 Cr on a trailing 12-month basis. An annual revenue de-growth of -9% needs improvement. The pre-tax margin of 11% is healthy, and ROE of 11% is good. The company is debt-free and has a strong balance sheet, enabling it to report stable earnings growth across business cycles.

Stock Performance and Valuation

Share Price Information

The stock trades on NSE under the symbol "MADHAVBAUG". The 52-week high price is ₹196.35 and the 52-week low price is ₹81.10. This wide range indicates significant volatility in the stock price over the past year.

Valuation Ratios

- P/E Ratio: 28.69 (as per recent data)

- P/B Ratio: 3.28

- Alternative P/E: 73.49 (from a different source)

- Alternative P/B: 2.62

Management and Corporate Governance

Mr. Rohit Madhav Sane is the CEO and Managing Director of the company. Mr. Darshan Shah is the Chief Financial Officer, and Mr. Mahesh P. Khirsagar, Mr. Ratnakar V. Rai, Mr. Vidyut B. Ghag, and Mr. Sushrut R. Dambal are directors of the company. The auditors are Vikrant Salunke & Associates.

The board includes Independent Director Mahesh P. Kshirsagar and Company Secretary & Compliance Officer Sapna Vaishnav. The Registered Office is located at 201 B Bhoomi Velocity Road, No. 23, Above ICICI Bank, Thane (W), Thane, Maharashtra - 400604.

Though the company is reporting repeated profits, it is not paying out a dividend, suggesting that the management is likely reinvesting profits back into the business for expansion and growth initiatives.

Industry Position and Peer Comparison

Vaidya Sane Ayurved Laboratories Ltd belongs to the Health Care sector & Labs & Life Sciences Services sub-sector. The peers of Vaidya Sane Ayurved Laboratories Ltd include Max Healthcare Institute Ltd, Apollo Hospitals Enterprise Ltd, Fortis Healthcare Ltd, Narayana Hrudayalaya Ltd, Global Health Ltd, Krishna Institute of Medical Sciences Ltd, and Aster DM Healthcare Ltd.

From an O'Neil Methodology perspective, the stock has an EPS Rank of 72, which is a FAIR score but needs to improve its earnings. It has an RS Rating of 88, which is GOOD, indicating outperformance compared to other stocks. Buyer Demand is at B+, evident from recent demand for the stock. The Group Rank of 24 indicates it belongs to a strong industry group of Medical-Hospitals, and a Master Score of B is close to being the best.

The company's unique positioning in the ayurvedic healthcare space differentiates it from traditional hospital chains, offering specialized treatments for chronic conditions through traditional medicine approaches combined with modern diagnostic capabilities. This niche focus provides competitive advantages in specific therapeutic areas while serving the growing demand for alternative healthcare solutions in India.